




Rapid and Accurate Molecular Identification of the Emerging Multidrug-Resistant Pathogen *Candida auris*

Milena Kordalewska,^a Yanan Zhao,^a Shawn R. Lockhart,^b  Anuradha Chowdhary,^c Indira Berrio,^{d,e,f} David S. Perlin^a

Public Health Research Institute, Rutgers Biomedical and Health Sciences, Newark, New Jersey, USA^a; Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA^b; Department of Medical Mycology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India^c; Clínica El Rosario, Medellín, Colombia^d; Medical and Experimental Mycology Group, Corporación para Investigaciones Biológicas (CIB), Medellín, Colombia^e; Hospital General de Medellín Luz Castro de Gutiérrez ESE, Medellín, Colombia^f

ABSTRACT *Candida auris* is an emerging multidrug-resistant fungal pathogen causing nosocomial and invasive infections associated with high mortality. *C. auris* is commonly misidentified as several different yeast species by commercially available phenotypic identification platforms. Thus, there is an urgent need for a reliable diagnostic method. In this paper, we present fast, robust, easy-to-perform and interpret PCR and real-time PCR assays to identify *C. auris* and related species: *Candida duobushaemulonii*, *Candida haemulonii*, and *Candida lusitanae*. Targeting rDNA region nucleotide sequences, primers specific for *C. auris* only or *C. auris* and related species were designed. A panel of 140 clinical fungal isolates was used in both PCR and real-time PCR assays followed by electrophoresis or melting temperature analysis, respectively. The identification results from the assays were 100% concordant with DNA sequencing results. These molecular assays overcome the deficiencies of existing phenotypic tests to identify *C. auris* and related species.

KEYWORDS *Candida duobushaemulonii*, *Candida haemulonii*, *Candida lusitanae*, *Candida auris*, PCR, diagnostics, identification, real-time PCR

Candida auris is an emerging multidrug-resistant yeast that can cause invasive infections and is associated with high mortality. It was first described in 2009 after being isolated from the external ear discharge of a patient in Japan (1). Since then, *C. auris* infections have been reported from South Korea (2, 3), India (4–6), Pakistan (5), Kuwait (7), Israel (8), South Africa (5, 9), the United Kingdom (10–12), Spain (13), the United States (14, 15), Colombia (16), and Venezuela (5, 17). The Centers for Disease Control and Prevention (CDC) and other research groups reported that almost all *C. auris* isolates are highly resistant to fluconazole, with the other azoles showing variable antifungal activity and isavuconazole and posaconazole being the most active ones. Moreover, up to one-third were resistant to amphotericin B, and a few were resistant to echinocandins. Some isolates demonstrated elevated MICs to all three major antifungal classes (azoles, echinocandins, and polyenes), indicating that treatment options against these multidrug-resistant isolates would be limited (18–20). *C. auris* is of great concern to public health agencies, due to the possibility that biologic and epidemiologic factors could trigger an even more extensive worldwide emergence of *C. auris* infections (21). Therefore, it is important for clinical microbiology and public health laboratories to rapidly and accurately identify this organism to help prevent health care-associated outbreaks and improve survival among infected patients by enabling appropriate early antifungal therapy implementation (22, 23).

Received 14 April 2017 Returned for modification 14 May 2017 Accepted 22 May 2017

Accepted manuscript posted online 24 May 2017

Citation Kordalewska M, Zhao Y, Lockhart SR, Chowdhary A, Berrio I, Perlin DS. 2017. Rapid and accurate molecular identification of the emerging multidrug-resistant pathogen *Candida auris*. *J Clin Microbiol* 55:2445–2452. <https://doi.org/10.1128/JCM.00630-17>.

Editor Daniel J. Diekema, University of Iowa College of Medicine

Copyright © 2017 Kordalewska et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Milena Kordalewska, milena.kordalewska@rutgers.edu, or David S. Perlin, perlinds@njms.rutgers.edu.

TABLE 1 Primers used in the study

Primer	Sequence	Specificity
CauF	5'-CGCACATTGCGCCTTGGGGTA-3'	<i>C. auris</i>
CauR	5'-GTAGTCCTACCTGATTTGAGGCGAC-3'	
CauRelF	5'-GCGATACGTAGTATGACTTGCAGACG-3'	<i>C. auris</i> and related species (<i>C. duobushaemulonii</i> , <i>C. haemulonii</i> , and <i>C. lusitaniae</i>)
CauRelR	5'-CAGCGGGTAGTCCTACCTGA-3'	

C. auris is phenotypically close to *Candida haemulonii* (1). It was reported that laboratories worldwide, relying on commercially available phenotypic platforms for yeast identification, commonly misidentify *C. auris* as *C. haemulonii* but also as several other yeast species (*C. famata*, *C. guilliermondii*, *C. lusitaniae*, *C. parapsilosis*, *C. sake*, *Rhodotorula glutinis*, and *Saccharomyces cerevisiae*) (18, 22, 24, 25). Moreover, some clinical laboratories do not identify all *Candida* to the species level, placing *C. auris* isolates in the "other *Candida* spp." category (18). Thus, the prevalence of *C. auris* is probably significantly underestimated due to unreliable identifications (4, 18, 25).

Given the current diagnostic urgency surrounding this pathogen, the aim of this work was to develop molecular-based methods that can quickly and accurately identify *C. auris* and related species (*C. duobushaemulonii*, *C. haemulonii*, and *C. lusitaniae*). The performance of the proposed methodology was evaluated using a comprehensive panel of clinical isolates with a wide spectrum of variable fungal species.

RESULTS

Primer design. The specific primers enabling the identification of *C. auris* and related species, *C. duobushaemulonii*, *C. haemulonii*, and *C. lusitaniae* are listed in Table 1. The designed amplicons cover a fragment of 5.8S, all of ITS2, and a fragment of 28S. CauF and CauR primers were designed to selectively amplify a 163-bp-long PCR product specific for *C. auris* only. CauRelF and CauRelR primers were designed to selectively amplify PCR products from either *C. auris*, *C. duobushaemulonii*, *C. haemulonii*, or *C. lusitaniae*. Amplified fragments differ in length (215 bp, 208 bp, 197 bp, and 203 bp, respectively) and composition and can be easily distinguished upon melting curve analysis.

***Candida auris*-specific PCR and real-time PCR assays.** A 163-bp PCR product specific for *Candida auris* was observed for all 44 *C. auris* DNA samples. No PCR products were detected for other yeast and mold isolates or human DNA (100% sensitivity and 100% specificity). Moreover, robust and reproducible amplicons were observed for all isolates when DNA extracts were replaced with a direct single-colony pick in the established assay (Fig. 1).

Similar results were obtained when real-time PCR was applied, as an amplicon with a melting temperature (T_m) of $85.1 \pm 0.2^\circ\text{C}$, corresponding to *C. auris*, was observed only for 44 *C. auris* DNA samples and not for any other fungal or human DNA samples (Fig. 2 and Table 2). The limit of detection (LOD) for the *C. auris*-specific assay was established at the level of 10 CFU/reaction (threshold cycle [C_T], 28.61 ± 0.25). The accuracy of the assay was confirmed by a proficiency test against a panel of 46 isolates (Table 3). The distribution of the amplicons' melting temperatures obtained for *C. auris* isolates is presented in Fig. 3.

***Candida auris* related-species-specific real-time PCR assay.** PCR products were observed for the following DNA samples: 7 *C. haemulonii* isolates (T_m , $84.8 \pm 0.2^\circ\text{C}$), 44 *C. auris* isolates (T_m , $85.6 \pm 0.15^\circ\text{C}$), 6 *C. duobushaemulonii* isolates (T_m , $86.2 \pm 0.1^\circ\text{C}$), and 6 *C. lusitaniae* isolates (T_m , $87.6 \pm 0.1^\circ\text{C}$). No PCR products were detected for other yeast and mold isolates or human DNA (100% sensitivity and 100% specificity) (Fig. 4 and Table 2). The LOD for the *C. auris* related species-specific assay was established at the level of 1,000 CFU/reaction (C_T , 27.83 ± 0.87). The accuracy of the assay was confirmed by testing a proficiency panel of 46 isolates (Table 3). The distribution of the




FIG 1 Example of *Candida auris*-specific PCR product analysis. M, 100-bp DNA ladder (fragment sizes 1,000, 900, 800, 700, 600, 500, 400, 300, 200, and 100 bp); A series, results of *Candida auris*-specific PCR; B series, results of colony *Candida auris*-specific PCR; lane 1, negative control; lane 2, *C. auris* VPCI 671/P/12; lane 3, *C. haemulonii* ATCC 22991; lane 4, *C. duobushaemulonii* B09383; lane 5, *C. lusitaniae* CAS08-0577; VPCI, Vallabhbhai Patel Chest Institute.

amplicons' melting temperatures obtained for *C. haemulonii*, *C. auris*, *C. duobushaemulonii*, and *C. lusitaniae* isolates is presented in Fig. 5.

DISCUSSION

In 2016, the CDC released an alert informing of an emerging pathogen, *Candida auris*, that is causing invasive infections (18), due to the challenging identification, common multidrug resistance, and outbreaks of this pathogen in health care settings (15).

A rapid and accurate identification of *C. auris* is important for not only the appro-




FIG 2 Melting profile of *Candida auris*-specific real-time PCR. 1, *C. auris* B11800 (Colombia); 2, *C. auris* VPCI 1133/P/13 (India); 3, *C. duobushaemulonii* CAS11-3561; 4, *C. lusitaniae* DPL 284; 5, *C. albicans* DPL 225; 6, *C. sake* 3000724892; 7, *Saccharomyces cerevisiae* DPL 269; 8, negative control; VPCI, Vallabhbhai Patel Chest Institute; DPL, David Perlin Laboratory.

TABLE 2 Specificity of *Candida auris*-specific and *Candida auris* related-species-specific assays

Species or organism	<i>Candida auris</i> -specific PCR No. of isolates detected/no. tested	Real-time PCR			
		<i>Candida auris</i> -specific		<i>Candida auris</i> related-species-specific	
		No. of isolates detected/no. tested	T_m (°C)	No. of isolates detected/no. tested	T_m (°C)
<i>C. auris</i>	44/44	44/44 (C_T , 19.4 ± 2.5)	85.1 ± 0.2	44/44 (C_T , 17.7 ± 1.8)	85.6 ± 0.15
<i>C. haemulonii</i>	0/7	0/7	— ^a	7/7 (C_T , 18.2 ± 1.3)	84.8 ± 0.2
<i>C. duobushaemulonii</i>	0/6	0/6	—	6/6 (C_T , 20.4 ± 0.7)	86.2 ± 0.1
<i>C. lusitanae</i>	0/6	0/6	—	6/6 (C_T , 20.1 ± 0.6)	87.6 ± 0.1
<i>C. albicans</i>	0/9	0/9	—	0/9	—
<i>C. glabrata</i>	0/10	0/10	—	0/10	—
<i>C. tropicalis</i>	0/11	0/11	—	0/11	—
<i>C. krusei</i>	0/10	0/10	—	0/10	—
<i>C. parapsilosis</i>	0/10	0/10	—	0/10	—
<i>C. metapsilosis</i>	0/4	0/4	—	0/4	—
<i>C. orthopsilosis</i>	0/3	0/3	—	0/3	—
<i>C. dubliniensis</i>	0/3	0/3	—	0/3	—
<i>C. guilliermondii</i>	0/4	0/4	—	0/4	—
<i>C. kefyr</i>	0/2	0/2	—	0/2	—
<i>C. famata</i>	0/1	0/1	—	0/1	—
<i>C. sake</i>	0/1	0/1	—	0/1	—
<i>Rhodotorula mucilaginosa</i>	0/3	0/3	—	0/3	—
<i>Saccharomyces cerevisiae</i>	0/2	0/2	—	0/2	—
<i>Aspergillus fumigatus</i>	0/1	0/1	—	0/1	—
<i>A. flavus</i>	0/1	0/1	—	0/1	—
<i>A. niger</i>	0/1	0/1	—	0/1	—
<i>Fusarium solani</i>	0/1	0/1	—	0/1	—
Human	0/1	0/1	—	0/1	—

^ano T_m .

priate use of antifungal treatment but also the implementation of effective infection control measures (12, 26). However, many laboratories do not routinely identify non-*albicans* *Candida* isolates to the species level, or they utilize phenotype-based yeast identification methods, such as chromogenic agar, biochemical tests, or automated systems, which commonly misidentify *C. auris* as many different yeast species. *C. auris* may be misidentified as *C. sake*, *Rhodotorula glutinis*, or *Saccharomyces cerevisiae* by API 20C AUX, as *C. haemulonii* by BD Phoenix, as *C. haemulonii* or *C. famata* by Vitek-2, or as *C. famata*, *C. lusitanae*, *C. guilliermondii*, or *C. parapsilosis* by MicroScan (12, 18, 22, 24,

TABLE 3 Proficiency panel results of *Candida auris*-specific and *Candida auris* related-species-specific assays

Species	<i>Candida auris</i> -specific real-time PCR		<i>Candida auris</i> related-species-specific real-time PCR	
	No. of isolates detected/no. tested	T_m (°C)	No. of isolates detected/no. tested	T_m (°C)
	<i>C. auris</i>	9/9 (C_T , 18.5 ± 1)	85.1 ± 0.1	9/9 (C_T , 18.3 ± 1.8)
<i>C. haemulonii</i>	0/7	— ^a	7/7 (C_T , 20.9 ± 0.6)	84.8 ± 0.15
<i>C. duobushaemulonii</i>	0/6	—	6/6 (C_T , 22.4 ± 1.2)	86.2 ± 0
<i>C. lusitanae</i>	0/6	—	6/6 (C_T , 21.6 ± 1.6)	87.6 ± 0.1
<i>C. albicans</i>	0/2	—	0/2	—
<i>C. glabrata</i>	0/2	—	0/2	—
<i>C. tropicalis</i>	0/2	—	0/2	—
<i>C. krusei</i>	0/2	—	0/2	—
<i>C. parapsilosis</i>	0/2	—	0/2	—
<i>C. dubliniensis</i>	0/1	—	0/1	—
<i>C. guilliermondii</i>	0/1	—	0/1	—
<i>C. kefyr</i>	0/1	—	0/1	—
<i>C. famata</i>	0/1	—	0/1	—
<i>C. sake</i>	0/1	—	0/1	—
<i>Rhodotorula mucilaginosa</i>	0/1	—	0/1	—
<i>Saccharomyces cerevisiae</i>	0/2	—	0/2	—

^ano T_m .




FIG 3 Distribution of melting temperatures of amplicons obtained for *C. auris* isolates in the *Candida auris*-specific real-time PCR assay.

25). Nowadays, proper identification of *Candida* species requires the application of specialized methods such as matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) or molecular identification based on sequencing the D1-D2 region of the 28S ribosomal DNA. However, due to the lack of *C. auris* entries in the FDA-approved libraries, it remains unidentified by Bruker Biotyper and Vitek-MS, and only when an additional research use only (RUO) library containing *C. auris* is incorporated can correct identification of this organism be obtained by both MALDI systems (25, 27).

In this study, we addressed the challenging identification of *Candida auris*. We present both conventional and real-time PCR assays that allow specific identification of *C. auris* and related species (*C. duobushaemulonii*, *C. haemulonii*, and *C. lusitaniae*) within 2 (real-time PCR and colony PCR) to 2.5 (conventional PCR) hours. To meet different diagnostic needs, we proposed two assays of different specificity ranges; the first assay identifies *C. auris* only, while in the second assay, *C. auris*, *C. duobushaemu-*




FIG 4 Melting analysis of *Candida auris* related-species-specific real-time PCR. 1, *C. haemulonii* ATCC 22991; 2, *C. auris* VPCI 1133/P/13; 3, *C. duobushaemulonii* CAS11-3561; 4, *C. lusitaniae* DPL 284; 5, *C. albicans* DPL 225; 6, *C. sake* 3000724892; 7, *Saccharomyces cerevisiae* DPL 269; 8, negative control; VPCI, Vallabhbhai Patel Chest Institute; DPL, David Perlin Laboratory.




FIG 5 Distribution of melting temperatures of amplicons obtained for *C. haemulonii*, *C. auris*, *C. duobushaemulonii*, and *C. lusitanae* isolates in the *Candida auris* related-species-specific real-time PCR assay.

lonii, *C. haemulonii*, and *C. lusitanae* can be identified and distinguished from each other. The differential specificities of the assays were obtained by a detailed analysis of rDNA sequences deposited in the NCBI nucleotide database that enabled the design of highly specific primers. Using 140 fungal isolates and human genomic DNA, we were able to identify *C. auris* isolates with 100% accuracy in all developed assays. Moreover, in *C. auris* related-species-specific real-time PCR, signature melting profiles and corresponding T_m values were generated for *C. auris*, *C. duobushaemulonii*, *C. haemulonii*, and *C. lusitanae*, enabling their unambiguous discrimination. Excellent results were achieved with both assays during the development phase, as well as during the proficiency panel validation.

In summary, we have developed two rapid, accurate, easy-to-perform and interpret molecular diagnostic assays to identify *C. auris* and related species (*C. duobushaemulonii*, *C. haemulonii*, and *C. lusitanae*) that overcome the deficiencies of existing phenotypic assays. Moreover, we expect that in the future, this diagnostic platform may be adjusted for the direct detection of *C. auris* in swabs from patients and from the hospital environment.

MATERIALS AND METHODS

Fungal isolates and culture conditions. In this study, we used a total of 140 fungal isolates (9 *C. albicans*, 44 *C. auris*, 3 *C. dubliniensis*, 6 *C. duobushaemulonii*, 1 *C. famata*, 10 *C. glabrata*, 4 *C. guilliermondii*, 7 *C. haemulonii*, 10 *C. krusei*, 6 *C. lusitanae*, 4 *C. metapsilosis*, 3 *C. orthopsilosis*, 10 *C. parapsilosis*, 2 *C. kefyri*, 1 *C. sake*, 11 *C. tropicalis*, 3 *Rhodotorula mucilaginosa*, 2 *Saccharomyces cerevisiae*, 1 *Aspergillus fumigatus*, 1 *A. flavus*, 1 *A. niger*, and 1 *Fusarium solani*) and 1 sample of human genomic DNA (Roche). Thirty-eight *C. auris* isolates were obtained from Vallabhbhai Patel Chest Institute, University of Delhi (Delhi, India), and 6 isolates were obtained from Clinica General del Norte (Barranquilla, Colombia). The remaining 96 laboratory and clinical isolates were stocked in the Perlin laboratory collection at the Public Health Research Institute (Newark, NJ, USA) (69 isolates) and the Fungal Reference Laboratory Collection at the Centers for Disease Control and Prevention (Atlanta, GA, USA) (27 isolates). Isolates were grown on yeast extract-peptone-dextrose (YPD) agar plates (at 24°C for *C. haemulonii*, *C. duobushaemulonii*, and *C. sake* isolates and at 37°C for all other isolates) prior to testing. Species identification of all *Candida* isolates was performed by sequencing of the rDNA region (partial sequences of the 18S and 28S rRNA genes and complete sequences of the internal transcribed spacer 1, 5.8S rRNA gene, and internal transcribed spacer 2), which was amplified with Fun-rDNAF (5'-GGTCATTAGAGGAAGTAAAGTCG-3') and Fun-rDNAR (5'-YGATATGCTTAAGTTCAGCGGTA-3') primers (S. Katiyar, personal communication), and further nucleotide BLAST analysis (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>).

DNA extraction. In all specificity tests and proficiency panel experiments, DNA from fungal isolates was prepared by a 10-min incubation of a single colony in 100 μ l of extraction buffer (60 mM sodium bicarbonate [NaHCO₃], 250 mM potassium chloride [KCl], and 50 mM Tris, pH 9.5) at 95°C and the subsequent addition of 100 μ l anti-inhibition buffer (2% bovine serum albumin). After vortex mixing, this DNA-containing solution was used for PCR (28). As for the analytical sensitivity evaluation experiments, DNA was isolated using a FastDNA kit (MP Biomedicals) according to the manufacturer's instruction.

Primer design. According to the rDNA sequence alignment (DNASTAR Lasergene 14), primers specific for *Candida auris* only or for *C. auris* and related species (*C. duobushaemulonii*, *C. haemulonii*, and *C. lusitanae*) were designed (Table 1). Primers were then synthesized by Integrated DNA Technologies.

Candida auris-specific PCR. PCR mixtures were prepared in a total volume of 30 μ l, consisting of 15 μ l of 2 \times EmeraldAmp MAX PCR master mix (TaKaRa Bio Inc.), 1 μ l of each primer (CauF and CauR) at 10 μ M, and 2 μ l of DNA. PCR was performed in a T100 thermal cycler (Bio-Rad Laboratories, Inc.). The thermal profile included an initial denaturation for 3 min at 95°C followed by 30 cycles of 20 s at 95°C, 20 s at 68°C, and 20 s at 72°C. The presence of amplicons was examined electrophoretically on 2% agarose gels stained with GelStar (Lonza).

Candida auris-specific and Candida auris related-species-specific real-time PCR. Species-specific and related-species-specific real-time PCR mixtures were 30 μ l per reaction, containing 15 μ l of 2 \times One-Step SYBR RT-PCR buffer IV, 1 μ l of PrimeScript enzyme mix II (TaKaRa Bio, Inc.), 1 μ l of each primer (CauF and CauR or CauRelF and CauRelR, respectively) at 10 μ M, and 2 μ l of DNA. Real-time PCR was performed on an Mx3005P qPCR system (Stratagene). The *Candida auris*-specific assay consisted of a 3-min incubation at 95°C, followed by 30 cycles of 15 s at 95°C, 20 s at 68°C, and 20 s at 72°C, and then 72°C for 5 min. The *Candida auris* related-species-specific assay consisted of a 3-min incubation at 95°C, followed by 30 cycles of 15 s at 95°C, 30 s at 66°C, and 30 s at 72°C, and then 72°C for 5 min. Immediately after amplification, a melting curve analysis was performed at 95°C for 1 min, and then from 70°C to 95°C with a ramp rate of 0.2°C/s.

Analytical sensitivity evaluation. The analytical sensitivity of the assays was determined by testing 10-fold serial dilutions of DNA samples ranging from 1 to 10⁶ CFU/reaction in triplicates. Two *C. auris* isolates were initially tested for the *Candida auris*-specific assay, and 1 *C. auris*, 1 *C. duobushaemulonii*, 1 *C. haemulonii*, and 1 *C. lusitanae* were used to evaluate the *Candida auris* related-species-specific assay. The LOD was determined as the smallest amount of template that elicited a positive C_T (threshold cycle) value and an unambiguous melting profile.

Proficiency panel. Real-time PCR assay performance was validated on a panel of 46 clinical isolates (2 *C. albicans*, 9 *C. auris*, 1 *C. dubliniensis*, 6 *C. duobushaemulonii*, 1 *C. famata*, 2 *C. glabrata*, 1 *C. guilliermondii*, 7 *C. haemulonii*, 2 *C. krusei*, 6 *C. lusitanae*, 2 *C. parapsilosis*, 1 *C. kefyr*, 1 *C. sake*, 2 *C. tropicalis*, 1 *Rhodotorula mucilaginosa*, and 2 *Saccharomyces cerevisiae*) pulled from the initial 140 isolates. The proficiency test was performed by a person who was blind to the sample identification (ID).

Colony Candida auris-specific PCR. To further reduce the time to diagnosis, we introduced a colony PCR into our diagnostic assay. Instead of using DNA extracts, a sterile toothpick was touched to a single colony and dipped into the PCR mixture, and then *Candida auris*-specific PCR was performed as described above. Forty-six clinical isolates pulled from the initial 140 isolates (proficiency panel) were tested for the efficiency of the colony PCR.

Statistical analysis. Melting temperature (T_m) values for each species were determined by melting curve analysis using the MxPro software (version 4.1) (Stratagene). The T_m distribution was analyzed by GraphPad Prism 6.05 software. The accuracies of the novel assays discriminating *C. auris* from other species were evaluated by calculating the sensitivity and specificity for each assay.

ACKNOWLEDGMENTS

We thank Anastasia P. Litvintseva, Elizabeth Berkow, and the CDC Fungal Reference Laboratory for their assistance with assay development. We also thank Annie Lee for her involvement in the analysis of the proficiency panel results.

All authors have no potential conflicts of interest. The authors alone are responsible for the content and writing of the paper.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

REFERENCES

- Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. 2009. *Candida auris* sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. *Microbiol Immunol* 53:41–44. <https://doi.org/10.1111/j.1348-0421.2008.00083.x>.
- Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH, Jang HC. 2011. First three reported cases of nosocomial fungemia caused by *Candida auris*. *J Clin Microbiol* 49:3139–3142. <https://doi.org/10.1128/JCM.00319-11>.
- Kim MN, Shin JH, Sung H, Lee K, Kim EC, Ryoo N, Lee JS, Jung SI, Park KH, Kee SJ, Kim SH, Shin MG, Suh SP, Ryang DW. 2009. *Candida haemulonii* and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. *Clin Infect Dis* 48: e57–e61. <https://doi.org/10.1086/597108>.
- Chowdhary A, Sharma C, Duggal S, Agarwal K, Prakash A, Singh PK, Jain S, Kathuria S, Randhawa HS, Hagen F, Meis JF. 2013. New clonal strain of *Candida auris*, Delhi, India. *Emerg Infect Dis* 19:1670–1673. <https://doi.org/10.3201/eid1910.130393>.
- Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, Colombo AL, Calvo B, Cuomo CA, Desjardins CA, Berkow EL, Castanheira M, Magobo RE, Jabeen K, Asghar RJ, Meis JF, Jackson B, Chiller T, Litvintseva AP. 2017. Simultaneous emergence of multidrug-resistant *Candida auris* on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. *Clin Infect Dis* 64:134–140. <https://doi.org/10.1093/cid/ciw691>.
- Chowdhary A, Anil Kumar V, Sharma C, Prakash A, Agarwal K, Babu R, Dinesh KR, Karim S, Singh SK, Hagen F, Meis JF. 2014. Multidrug-resistant endemic clonal strain of *Candida auris* in India. *Eur J Clin Microbiol Infect Dis* 33:919–926. <https://doi.org/10.1007/s10096-013-2027-1>.
- Emara M, Ahmad S, Khan Z, Joseph L, Al-Obaid I, Purohit P, Bafna R. 2015. *Candida auris* candidemia in Kuwait, 2014. *Emerg Infect Dis* 21: 1091–1092. <https://doi.org/10.3201/eid2106.150270>.
- Ben-Ami R, Berman J, Novikov A, Bash E, Shachor-Meyouhas Y, Zakin S, Maor Y, Tarabia J, Schechner V, Adler A, Finn T. 2017. Multidrug-resistant *Candida haemulonii* and *C. auris*, Tel Aviv, Israel. *Emerg Infect Dis* 23:195–203. <https://doi.org/10.3201/eid2302.161486>.
- Magobo RE, Corcoran C, Seetharam S, Govender NP. 2014. *Candida auris*-associated candidemia, South Africa. *Emerg Infect Dis* 20: 1250–1251. <https://doi.org/10.3201/eid2007.131765>.
- Borman AM, Szekely A, Johnson EM. 16 February 2017. Isolates of the

- emerging pathogen *Candida auris* present in the UK have several geographic origins. *Med Mycol* <https://doi.org/10.1093/mmy/myw147>.
11. Borman AM, Szekeley A, Johnson EM. 2016. Comparative pathogenicity of United Kingdom isolates of the emerging pathogen *Candida auris* and other key pathogenic *Candida* species. *mSphere* 1:e00189-16. <https://doi.org/10.1128/mSphere.00189-16>.
 12. Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, Ryan L, Shackleton J, Trimlett R, Meis JF, Armstrong-James D, Fisher MC. 2016. First hospital outbreak of the globally emerging *Candida auris* in a European hospital. *Antimicrob Resist Infect Control* 5:35. <https://doi.org/10.1186/s13756-016-0132-5>.
 13. Ruiz Gaitan AC, Moret A, Lopez Hontangas JL, Molina JM, Aleixandre Lopez AI, Cabezas AH, Mollar Maseres J, Arcas RC, Gomez Ruiz MD, Chiveli MA, Canton E, Peman J. 2017. Nosocomial fungemia by *Candida auris*: first four reported cases in continental Europe. *Rev Iberoam Micol* 34:23–27. <https://doi.org/10.1016/j.riam.2016.11.002>.
 14. McCarthy M. 2016. Hospital transmitted *Candida auris* infections confirmed in the US. *BMJ* 355:i5978. <https://doi.org/10.1136/bmj.i5978>.
 15. Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, Kemble SK, Pacilli M, Black SR, Landon E, Ridgway J, Palmore TN, Zelzany A, Adams EH, Quinn M, Chaturvedi S, Greenko J, Fernandez R, Southwick K, Furuya EY, Calfee DP, Hamula C, Patel G, Barrett P, Lafaro P, Berkow EL, Moulton-Meissner H, Noble-Wang J, Fagan RP, Jackson BR, Lockhart SR, Litvintseva AP, Chiller TM. 2017. Investigation of the first seven reported cases of *Candida auris*, a globally emerging invasive, multidrug-resistant fungus—United States, May 2013–August 2016. *Am J Transplant* 17:296–299. <https://doi.org/10.1111/ajt.14121>.
 16. Morales-Lopez SE, Parra-Giraldo CM, Ceballos-Garzon A, Martinez HP, Rodriguez GJ, Alvarez-Moreno CA, Rodriguez JY. 2017. Invasive infections with multidrug-resistant yeast *Candida auris*, Colombia. *Emerg Infect Dis* 23:162–164. <https://doi.org/10.3201/eid2301.161497>.
 17. Calvo B, Melo AS, Perozo-Mena A, Hernandez M, Francisco EC, Hagen F, Meis JF, Colombo AL. 2016. First report of *Candida auris* in America: clinical and microbiological aspects of 18 episodes of candidemia. *J Infect* 73:369–374. <https://doi.org/10.1016/j.jinf.2016.07.008>.
 18. Centers for Disease Control and Prevention. 2016. Clinical alert to U.S. healthcare facilities—June 2016. Centers for Disease Control and Prevention, Atlanta, GA. <https://www.cdc.gov/fungal/diseases/candidiasis/candida-auris-alert.html>. Accessed 24 February 2017.
 19. Larkin E, Hager C, Chandra J, Mukherjee PK, Retuerto M, Salem I, Long L, Isham N, Kovanda L, Borroto-Esoda K, Wring S, Angulo D, Ghannoum M. 21 February 2017. The emerging *Candida auris*: characterization of growth phenotype, virulence factors, antifungal activity, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation. *Antimicrob Agents Chemother* <https://doi.org/10.1128/AAC.02396-16>.
 20. Arendrup MC, Prakash A, Meletiadis J, Sharma C, Chowdhary A. 17 April 2017. *Candida auris*: comparison of the EUCAST and CLSI reference microdilution MICs for eight antifungal compounds and associated tentative ECOFFs. *Antimicrob Agents Chemother* <https://doi.org/10.1128/AAC.00485-17>.
 21. Clancy CJ, Nguyen MH. 2017. Emergence of *Candida auris*: an international call to arms. *Clin Infect Dis* 64:141–143. <https://doi.org/10.1093/cid/ciw696>.
 22. Mizusawa M, Miller H, Green R, Lee R, Durante M, Perkins R, Hewitt C, Simmer PJ, Carroll KC, Hayden RT, Zhang SX. 2017. Can multidrug-resistant *Candida auris* be reliably identified in clinical microbiology laboratories? *J Clin Microbiol* 55:638–640. <https://doi.org/10.1128/JCM.02202-16>.
 23. Patel GP, Simon D, Scheetz M, Crank CW, Lodise T, Patel N. 2009. The effect of time to antifungal therapy on mortality in candidemia associated septic shock. *Am J Ther* 16:508–511. <https://doi.org/10.1097/MJT.0b013e3181a1afb7>.
 24. Britz E, Govender NP. 2016. Global emergence of a multi-drug resistant fungal pathogen, *Candida auris*. *S Afr J Infect Dis* 31(3):3–4. <https://doi.org/10.1080/23120053.2016.1221613>.
 25. Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, Meis JF, Chowdhary A. 2015. Multidrug-Resistant *Candida auris* misidentified as *Candida haemulonii*: characterization by matrix-assisted laser desorption/ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. *J Clin Microbiol* 53:1823–1830. <https://doi.org/10.1128/JCM.00367-15>.
 26. Chowdhary A, Voss A, Meis JF. 2016. Multidrug-resistant *Candida auris*: ‘new kid on the block’ in hospital-associated infections? *J Hosp Infect* 94:209–212. <https://doi.org/10.1016/j.jhin.2016.08.004>.
 27. Girard V, Mailler S, Chetry M, Vidal C, Durand G, van Belkum A, Colombo AL, Hagen F, Meis JF, Chowdhary A. 2016. Identification and typing of the emerging pathogen *Candida auris* by matrix-assisted laser desorption/ionisation time of flight mass spectrometry. *Mycoses* 59:535–538. <https://doi.org/10.1111/myc.12519>.
 28. Brillowska-Dabrowska A, Nielsen SS, Nielsen HV, Arendrup MC. 2010. Optimized 5-hour multiplex PCR test for the detection of tinea unguium: performance in a routine PCR laboratory. *Med Mycol* 48:828–831. <https://doi.org/10.3109/13693780903531579>.